Last. Philip Van Damme(Katholieke Universiteit Leuven)H-Index: 51
view all 4 authors...
We describe a unique case of a patient with primary lateral sclerosis (PLS), initially presenting with unilateral mild paresis and slowing of the upper limb and a full imaging work-up including MRI, [18F]FDG PET and presynaptic dopaminergic imaging (using both [123I]FP-CIT SPECT and more accurate [18F]PE2I PET).
A 40-year-old woman with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection developed neurologic manifestations (confusion, agitation, seizures, dyskinesias, and parkinsonism) few weeks after SARS onset. Magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analyses were unremarkable, but an 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) showed limbic and extra-limbic hypermetabolism. A full recovery, alongside FDG normalizat...
177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a mCRPC patient with M1c disease (mediastinum, lungs, bones and liver) who presented with elevated liver enzyme levels after 177Lu-PSMA-RLT administration. Pre-treatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake....
#1Jorianne Boers(UMCG: University Medical Center Groningen)H-Index: 2
#2Naila Loudini(UMCG: University Medical Center Groningen)H-Index: 1
Last. Carolina P. Schröder(UMCG: University Medical Center Groningen)H-Index: 18
view all 8 authors...
Background: Breast cancer (BC) is a heterogeneous disease, in which estrogen receptor (ER) expression plays an important role in the majority of breast tumors. A clinical dilemma may arise when a metastasis biopsy to determine the ER status cannot be performed safely or when ER heterogeneity is suspected between tumor lesions. Whole-body ER imaging, such as 16α-18F-fluoro-17β-estradiol (18F-FES) positron emission tomography (PET), may have added value in these situations. However, the role of th...
Last. Manuel Weber(University of Duisburg-Essen)H-Index: 12
view all 13 authors...
Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework for disease volume assessment in mHSPC. Methods: Three PET centers screened their PSMA-PET database for mHSPC patients. CT versus PSMA-PET stage, lesion number, and classification of LVD vs. HVD were determined by one blinded reader; PSMA-positive tumo...
#2Elise Bekers(NKI-AVL: Netherlands Cancer Institute)H-Index: 3
Last. Oscar R. Brouwer(NKI-AVL: Netherlands Cancer Institute)H-Index: 16
view all 8 authors...
In penile squamous cell carcinoma (pSCC), primary surgery aims to obtain oncologically safe margins while minimizing mutilation. Surgical guidance provided by receptor-specific tracers could potentially improve margin detection and reduce unnecessary excision of healthy tissue. Here, we present the first results of a prospective feasibility study for real-time intraoperative visualization of pSCC using a fluorescent mesenchymal–epithelial transition factor (c-MET) receptor targeting tracer (EMI-...
Knowledge of the intrinsic variability of radiomic features is essential to the proper interpretation of changes in these features over time. The primary aim of this study was to assess the test-retest repeatability of radiomic features extracted from 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) images of cervical tumors. The impact of different image pre-processing methods was also explored. Methods: Patients with cervical cancer underwent baseline and repeat FDG PET/CT imagi...
Last. Ann D. Cohen(University of Pittsburgh)H-Index: 26
view all 16 authors...
In this review we examine, in the context of the AT(N) framework, the available evidence as well as the potential alternatives on how to establish tau-positivity (T+) for multiple tau imaging tracers in order to come to a consensus for "normal" and "abnormal" tau imaging values that can be universally implemented in clinical research and therapeutic trials.